PBAC's latest decision on Sacubitril with valsartan: Recommended (2024). Considered for Treatment of chronic heart failure (NYHA Class II-IV) with reduced left ventricular ejection fraction in adult patients. This submission specifically requested amendment to allow nurse practitioners to initiate treatment.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
3
first 2016
Submissions
3
2016 → 2024
Eligible population
Adults with chronic heart failure (NYHA Class II-IV) and documented left ventricular ejection fraction ≤40% who are symptomatic and receiving concomitant optimal standard heart failure treatment
Therapy area
Cardiovascular
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Economic model
BIA only
ICER note
not-modelled — this is a Category 4 minor submission for a prescriber-type amendment (nurse practitioner initiation rights) with no new economic evaluation
Submission history
Mar 2016: Not recommended · Authority Required
Jul 2016: Recommended with restriction · Restricted